Ascendis Pharma A/S (ASND) – What Are Analysts Saying About This Stock?

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Moderate Buy” from the twenty-one research firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $313.52.

A number of analysts recently commented on ASND shares. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Sunday, November 8th. Bank of America reduced their price objective on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Oppenheimer increased their price objective on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Royal Bank Of Canada set a $352.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. Finally, Wedbush reiterated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Allworth Financial LP grew its position in Ascendis Pharma A/S by 103.4% during the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after buying an additional 122 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 69 shares during the period. Fifth Third Bancorp raised its stake in shares of Ascendis Pharma A/S by 48.4% in the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 91 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 148 shares in the last quarter. Finally, IFP Advisors Inc lifted its position in Ascendis Pharma A/S by 3,491.7% in the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 419 shares during the period.

Latest Ascendis Pharma A/S News

Investors following ASND have been watching these news items:

• Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
• Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
• Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock traded up $8.32 during trading hours on Friday, reaching $275.39. The stock had a trading volume of 826,059 shares, compared to its average volume of 694,460. The firm has a 50-day simple moving average of $242.67 and a 200-day simple moving average of $239.83. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The firm has a market capitalization of $17.18 billion, a PE ratio of 18.00 and a beta of 0.40. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 44.80%. The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.